How to verify Cagrilintide purity and batch documentation
A research-use guide to verifying Cagrilintide purity and batch documentation, covering analytical methods, study evidence, and documentation requirements for laboratory supply.
To verify Cagrilintide purity and batch documentation, a laboratory should require a compound-specific certificate of analysis (CoA) that reports the actual analytical result for the batch in hand, not a specification sheet or a generic product page. The formal name is cagrilintide; it is a long-acting amylin receptor agonist peptide developed as a monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide, known as CagriSema [4]. The evidence block supplied for this page does not give a sequence, molecular formula, or molecular weight, so those identifiers cannot be stated here. What the evidence does establish is the receptor family: the work centres on amylin receptor signalling, with Calcr-expressing neuronal populations in the dorsal vagal complex identified as mediators of cagrilintide action in animal models [3].
Purity verification is an analytical exercise, not a marketing claim. A usable batch record ties a specific lot number to a specific analytical result, and the methods used to generate that result should be named. The studies cited below are clinical, animal, or in vitro; none of them validate a supplier's CoA, and none of them should be read as a purity standard. They are included because they define what cagrilintide is, how it behaves in defined populations, and where the evidence stops.
Research Studies
Cagrilintide and amylin receptor signalling in the dorsal vagal complex
A cross-species transcriptomic atlas covering more than 530,000 cells and 80 neuronal cell populations across rat, mouse, and macaque caudal brainstem, with spatial profiling in the rat dorsal vagal complex, identified two conserved Calcr-expressing DVC neuronal populations regulated by cagrilintide [3]. Acute treatment altered gene expression in area postrema Calcr/Ramp3 neurons, but chemogenetic activation of those neurons in rats did not affect long-term food intake or body weight. Long-term cagrilintide treatment in rats produced a different pattern [3]. This is animal and in vitro work; it does not establish a human mechanism, and it does not speak to peptide purity.
Cagrilintide and food intake in people with overweight or obesity
A clinical study is testing cagrilintide to understand how it affects food intake and appetite in people with overweight or obesity, with participants randomised to cagrilintide or placebo and followed for about 30 weeks [8]. This is a registered human study; results are not reported in the evidence block, so no effect size can be stated.
Cagrilintide and renal or hepatic impairment
Two studies assessed the effects of renal or hepatic impairment on pharmacokinetics, safety, and tolerability after single doses of cagrilintide [4]. Adult participants were categorised into four groups by renal or hepatic function — normal function and mild, moderate, or severe impairment — and received a single dose of cagrilintide 0.6 or 0.9 (units not specified in the evidence block). The reported finding is that renal or hepatic impairment did not affect pharmacokinetics, safety, or tolerability of subcutaneous cagrilintide [4]. This is human pharmacokinetic data; it is not a purity assay.
Cagrilintide and tolerability in people who do not tolerate GLP-1 receptor agonists
A clinical study is examining the safety of cagrilintide compared with placebo in people who do not tolerate marketed GLP-1 therapies and who live with overweight or obesity, with a study duration of about 8 months [5]. This addresses a defined population — GLP-1-intolerant individuals — and the evidence block reports the design, not the outcome.
Cagrilintide and comparison of two injectable versions
A clinical study compares two different versions of injectable cagrilintide and placebo in people with excess body weight, with participants followed for about 9 months [1]. A separate study compares blood levels of two versions, cagrilintide B and cagrilintide D, in adults with excess body weight over about 14 weeks [6]. A third study compares blood levels after multiple doses of cagrilintide version D or version B in adults with overweight or obesity over about 6 months [7]. These are formulation-comparison studies in humans; they do not report analytical purity data.
Cagrilintide and comparative effectiveness across advanced anti-obesity medications
A network meta-analysis examined the comparative efficacy and safety of tirzepatide, semaglutide, cagrilintide, and their combination CagriSema, noting that no direct head-to-head studies had compared all advanced anti-obesity medications [2]. The analysis searched PubMed, Scopus, and Cochrane Central for randomised clinical trials [2]. This is a synthesis of human trial data; it is not a batch-release document.
Cagrilintide and combination therapy in obese male rats
A study reports enhanced metabolic benefits from combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GC receptor agonist, in obese male rats [9]. This is animal-only evidence and should be labelled as such in any research note.
Cagrilintide and amylin-based therapy meta-analysis
A systematic review and meta-analysis evaluated amylin-based obesity therapy, covering cagrilintide and its fixed-dose combination with semaglutide, CagriSema, versus placebo [10]. This is a synthesis of human trial data.
Cagrilintide-semaglutide in type 2 diabetes
The REIMAGINE 1 phase 3a study assessed once-weekly cagrilintide-semaglutide in adults with type 2 diabetes inadequately controlled on diet and exercise [11]. The REIMAGINE 2 phase 3 study compared cagrilintide-semaglutide with semaglutide or cagrilintide in people with type 2 diabetes [12]. Both are human randomised controlled trials of the fixed-dose combination, not of cagrilintide alone.
What a batch record should contain
Because the evidence block does not supply a purity specification, the following is a documentation checklist rather than a numeric standard. A laboratory receiving a cagrilintide lot should be able to match the lot number on the vial to the lot number on the CoA, and the CoA should name the analytical methods used. Typical methods for peptide identity and purity include high-performance liquid chromatography (HPLC) for purity and mass spectrometry (MS) for identity, but the evidence block does not state which methods were used for any cagrilintide batch, so no method can be attributed to this compound from these sources.
| Documentation element | What it should establish | Evidence status |
|---|---|---|
| Lot-specific CoA | Links the batch in hand to an analytical result | Not addressed in the evidence block |
| Purity method (e.g., HPLC) | Names the separation method and result | Not addressed in the evidence block |
| Identity method (e.g., MS) | Confirms molecular identity | Not addressed in the evidence block |
| Sequence, formula, molecular weight | Defines the molecule | Not provided in the evidence block |
| Storage and handling | Defines stability conditions | Not addressed in the evidence block |
Where the evidence is animal-only or in vitro
The dorsal vagal complex atlas work is animal and in vitro: rat, mouse, and macaque tissue, with chemogenetic manipulation in rats [3]. The retatrutide combination study is animal-only, in obese male rats [9]. The remaining cited studies are human: registered clinical trials [1][5][6][7][8], human pharmacokinetic studies [4], and meta-analyses or randomised trials in human populations [2][10][11][12]. No cited study validates a supplier's purity claim, and no cited study provides a batch-release specification.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.
Sources
- [1] A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight — https://clinicaltrials.gov/study/NCT07745504
- [2] Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials — https://europepmc.org/article/PMC/PMC13239642
- [3] A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance — https://europepmc.org/article/PMC/PMC13303089
- [4] Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide — https://europepmc.org/article/PMC/PMC13356073
- [5] Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — https://clinicaltrials.gov/study/NCT07607587
- [6] A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight — https://clinicaltrials.gov/study/NCT07605052
- [7] A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity — https://clinicaltrials.gov/study/NCT07597018
- [8] A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity — https://clinicaltrials.gov/study/NCT07557953
- [9] Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats — https://pubmed.ncbi.nlm.nih.gov/42744908/
- [10] Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo — https://europepmc.org/article/PMC/PMC13461105
- [11] Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1) — https://pubmed.ncbi.nlm.nih.gov/42251860/
- [12] Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2) — https://pubmed.ncbi.nlm.nih.gov/42251859/